BioCryst Pharmaceuticals (BCRX) Competitors $8.85 +0.41 (+4.86%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$8.89 +0.04 (+0.45%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCRX vs. IONS, ALKS, FOLD, LGND, MNKD, DVAX, CLDX, INVA, NVAX, and OPKShould you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), MannKind (MNKD), Dynavax Technologies (DVAX), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. BioCryst Pharmaceuticals vs. Ionis Pharmaceuticals Alkermes Amicus Therapeutics Ligand Pharmaceuticals MannKind Dynavax Technologies Celldex Therapeutics Innoviva Novavax OPKO Health BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings. Do analysts rate BCRX or IONS? BioCryst Pharmaceuticals presently has a consensus price target of $16.13, indicating a potential upside of 82.20%. Ionis Pharmaceuticals has a consensus price target of $56.44, indicating a potential upside of 83.80%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than BioCryst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Ionis Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.70 Which has stronger earnings & valuation, BCRX or IONS? BioCryst Pharmaceuticals has higher earnings, but lower revenue than Ionis Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCryst Pharmaceuticals$450.71M4.10-$226.54M-$0.43-20.58Ionis Pharmaceuticals$705.14M6.92-$366.29M-$3.04-10.10 Does the media refer more to BCRX or IONS? In the previous week, Ionis Pharmaceuticals had 11 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 20 mentions for Ionis Pharmaceuticals and 9 mentions for BioCryst Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.17 beat BioCryst Pharmaceuticals' score of 0.78 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 13 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in BCRX or IONS? Ionis Pharmaceuticals received 213 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. However, 66.94% of users gave BioCryst Pharmaceuticals an outperform vote while only 60.36% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBioCryst PharmaceuticalsOutperform Votes49266.94% Underperform Votes24333.06% Ionis PharmaceuticalsOutperform Votes70560.36% Underperform Votes46339.64% Do institutionals and insiders believe in BCRX or IONS? 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, BCRX or IONS? BioCryst Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Is BCRX or IONS more profitable? BioCryst Pharmaceuticals has a net margin of -30.01% compared to Ionis Pharmaceuticals' net margin of -64.25%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioCryst Pharmaceuticals-30.01% N/A -24.06% Ionis Pharmaceuticals -64.25%-100.05%-15.70% SummaryIonis Pharmaceuticals beats BioCryst Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCRX vs. The Competition Export to ExcelMetricBioCryst PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$3.00B$5.56B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-14.5130.4222.5118.48Price / Sales4.10498.92395.68103.60Price / CashN/A168.6838.1834.62Price / Book-3.993.206.774.25Net Income-$226.54M-$72.35M$3.22B$248.23M7 Day Performance7.66%1.46%1.45%0.89%1 Month Performance22.07%8.79%3.97%3.53%1 Year Performance93.65%-22.36%16.14%5.08% BioCryst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCRXBioCryst Pharmaceuticals4.4625 of 5 stars$8.85+4.9%$16.13+82.2%+114.3%$1.85B$450.71M-14.51530Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageIONSIonis Pharmaceuticals4.1826 of 5 stars$28.51+0.4%$56.72+99.0%-25.6%$4.53B$705.14M-9.38800Earnings ReportAnalyst ForecastNews CoveragePositive NewsGap UpALKSAlkermes4.617 of 5 stars$27.00flat$38.50+42.6%+17.2%$4.45B$1.56B12.442,280Analyst ForecastNews CoverageFOLDAmicus Therapeutics4.3734 of 5 stars$6.71-1.8%$16.75+149.6%-23.1%$2.06B$528.30M-37.28480Earnings ReportNews CoveragePositive NewsLGNDLigand Pharmaceuticals4.3875 of 5 stars$104.81-0.2%$146.43+39.7%+57.2%$2.02B$167.13M41.7680Upcoming EarningsNews CoverageMNKDMannKind3.1294 of 5 stars$4.44-2.2%$9.56+115.4%+22.6%$1.35B$285.50M63.43400Upcoming EarningsPositive NewsDVAXDynavax Technologies4.2926 of 5 stars$10.44+1.3%$20.50+96.4%+3.3%$1.30B$277.25M58.00350Upcoming EarningsCLDXCelldex Therapeutics1.9841 of 5 stars$18.94+3.5%$54.33+186.9%-44.3%$1.26B$7.02M-7.37150Positive NewsINVAInnoviva4.2229 of 5 stars$18.28+0.1%$55.00+200.9%+23.7%$1.15B$358.71M26.49100Upcoming EarningsAnalyst UpgradeNews CoveragePositive NewsNVAXNovavax3.6228 of 5 stars$6.01+0.2%$18.00+199.5%+54.0%$966.67M$682.16M-2.661,990OPKOPKO Health4.4662 of 5 stars$1.37-3.5%$2.75+100.7%+13.1%$920.02M$713.14M-7.214,200Earnings ReportNews Coverage Related Companies and Tools Related Companies IONS Competitors ALKS Competitors FOLD Competitors LGND Competitors MNKD Competitors DVAX Competitors CLDX Competitors INVA Competitors NVAX Competitors OPK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCRX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCRX Stock Free BCRX Stock Alerts